SCHEMBL4838441

SCHEMBL4838441

COC(=O)C(CC(=O)O)CC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
CYP2D6 P10635 1/20 0.41
CA2 P00918 3/20 0.38
CA1 P00915 1/20 0.38
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CA12 O43570 2/20 0.35
CA14 Q9ULX7 2/20 0.35
DGAT1 O75907 1/20 0.34
CA9 Q16790 1/20 0.33
MME P08473 1/20 0.33
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KLK5 Q9Y337 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8133983 0.89 CYP2D6 (0.39) KMT2ACYP2D6CA2MEN1GAA
SCHEMBL6248155 0.89 CYP2D6 (0.39) KMT2ACYP2D6CA2MEN1GAA
SCHEMBL6250770 0.89 CYP2D6 (0.39) KMT2ACYP2D6CA2MEN1GAA
SCHEMBL34469067 0.86 KMT2A (0.37) KMT2ACYP2D6CA2CA1MEN1
SCHEMBL4835503 0.85 FOLH1 (0.39) KMT2ACYP2D6CA2CA1MEN1
SCHEMBL8669431 0.83 KMT2A (0.47) KMT2ACA2CA1GAAMME
SCHEMBL584778 0.82 KMT2A (0.53) KMT2ACA2CA1MME
SCHEMBL6762851 0.82 CYP2D6 (0.41) KMT2ACYP2D6CA2CA1MEN1
SCHEMBL27708785 0.82 CYP2D6 (0.41) KMT2ACYP2D6CA2CA1MEN1
SCHEMBL8204187 0.81 CYP2D6 (0.38) KMT2ACYP2D6CA2CA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD KMT2A 2453/4885CYP2D6 1738/4885CA2 333/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD KMT2A 2577/4885CYP2D6 1525/4885CA2 344/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH KMT2A 2487/4885CYP2D6 1504/4885CA2 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.